Cidara Therapeutics presents data on CD388 from Phase 2b NAVIGATE trial

Cidara Therapeutics (CDTX) announced two presentations during the International Society for Respiratory Viruses, ISRV, 8th AntiViral Group, AVG, Meeting and 3rd International Meeting on Respiratory Pathogens, IMRP. The conference is taking place September 17-20, 2025, in Singapore. The presentations highlight efficacy and safety data on CD388, Cidara’s non-vaccine influenza preventative, from the successful Phase 2b NAVIGATE study, as well as preclinical data on the efficacy of CD388 to prevent infection in H5N1 animal models. “These two oral presentations further highlight the potential of CD388 to provide season long protection against influenza as well as activity against highly pathogenic pandemic strains like H5N1,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “The Phase 2b presentation represents the first description of CD388 NAVIGATE study data in an academic setting. Importantly, the preclinical results of CD388 in a ferret model suggests that CD388 has the potential to provide prophylactic protection from this potentially deadly viral infection. We look forward to disclosing additional details on the safety, PK and virology data from our Phase 2b NAVIGATE study at upcoming conferences this fall.”